导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 3.84% | 1319/4773 |
| 近一周 | -1.44% | 450/5462 |
| 近一月 | -2.16% | 1184/5421 |
| 近一季 | -5.20% | 1788/5209 |
| 近半年 | 2.38% | 974/4920 |
| 近一年 | 7.89% | 1249/4366 |
| 近两年 | 55.45% | 1327/2954 |
| 近三年 | 44.89% | 627/2253 |
| 成立以来 | 76.32% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-2.42% 2783/4961 |
14.75% 1765/5312 |
- - |
- - |
| 2025 | 22.55% 1958/4813 |
-0.15% 2085/3635 |
4.15% 847/4076 |
16.05% 2729/4524 |
1.54% 1342/4813 |
| 2024 | 18.60% 588/3463 |
3.75% 517/2808 |
0.72% 555/3014 |
14.44% 1973/3129 |
-0.83% 1527/3463 |
| 2023 | -4.64% 688/2656 |
4.27% 1000/2280 |
-2.75% 650/2385 |
-1.59% 554/2515 |
-4.44% 1036/2655 |
| 2022 | -21.18% 1013/2207 |
-13.58% 791/1919 |
7.20% 512/2016 |
-12.19% 665/2113 |
-3.11% 1834/2208 |
| 2021 | -2.36% 849/1822 |
-3.39% 804/1255 |
6.35% 759/1330 |
-5.10% 778/1466 |
0.13% 1168/1822 |
| 2020 | 41.96% 279/1250 |
-6.99% 520/1028 |
17.36% 375/1067 |
15.24% 228/1164 |
12.85% 423/1184 |
| 2019 | - - |
- - |
- - |
1.93% 343/850 |
8.77% 291/918 |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 博道沪深300指数增强C VS. 长安沪深300非周期A(740101) |